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he mitotic checkpoint prevents cells with unaligned
chromosomes from prematurely exiting mitosis by
inhibiting the anaphase-promoting complex/cyclosome
(APC/C) from targeting key proteins for ubiquitin-mediated
proteolysis. We have examined the mechanism by which
the checkpoint inhibits the APC/C by purifying an APC/C
inhibitory factor from HeLa cells. We call this factor the
mitotic checkpoint complex (MCC) as it consists of
hBUBR1, hBUB3, CDC20, and MAD2 checkpoint proteins
in near equal stoichiometry. MCC inhibitory activity is
3,000-fold greater than that of recombinant MAD2, which
has also been shown to inhibit APC/C in vitro. Surprisingly,
T
 
MCC is not generated from kinetochores, as it is also
present and active in interphase cells. However, only APC/C
 
isolated from mitotic cells was sensitive to inhibition by MCC.
We found that the majority of the APC/C in mitotic lysates is
associated with the MCC, and this likely contributes to the
lag in ubiquitin ligase activity. Importantly, chromosomes
can suppress the reactivation of APC/C. Chromosomes did
not affect the inhibitory activity of MCC or the stimulatory
activity of CDC20. We propose that the preformed inter-
phase pool of MCC allows for rapid inhibition of APC/C
when cells enter mitosis. Unattached kinetochores then
target the APC/C for sustained inhibition by the MCC.
 
Introduction
 
The mitotic checkpoint ensures chromosomes are accurately
segregated by preventing cells with unaligned chromosomes
from exiting mitosis (Rieder and Salmon, 1998; Skibbens and
Hieter, 1998; Zacharie and Nasmyth, 1999). Minimally, this
pathway consists of three components: a sensor that detects
the presence of unaligned chromosomes, an effector or
transducer that relays or amplifies the signal generated by
the sensor, and an inhibitor that is capable of stopping the
cell cycle progression until after all chromosomes are prop-
erly aligned. This scheme is derived from early work that
showed that a single unattached kinetochore can generate
sufficient amounts of an inhibitory signal to prevent a cell
from exiting from mitosis (Rieder et al., 1995). Molecular
mechanisms that explain the different segments of this
checkpoint pathway remain to be established, but recent
work has identified many components of the system. The
mitotic checkpoint pathway is specified by a group of evolu-
tionarily conserved genes that include MAD1, MAD2, MAD3,
BUB1, and BUB3 (Hoyt et al., 1991; Li and Murray, 1991;
Roberts et al., 1994; Hardwick and Murray, 1995; Li and
Benezra, 1996). These proteins preferentially associate
with kinetochores of unaligned chromosomes where they
are hypothesized to monitor and generate the inhibitory sig-
nal that delays the metaphase to anaphase transition (Chen et
al., 1996, 1998; Taylor and McKeon, 1997; Taylor et al.,
1998; Waters et al., 1998; Chan et al., 1999; Shah and
Cleveland, 2000). This delay is achieved by inhibiting the
anaphase-promoting complex/cyclosome (APC/C),* a multi-
subunit E3 ubiquitin ligase that targets key proteins whose
destruction is necessary for sister chromatid separation and
exit from mitosis (King et al., 1995, 1996; Sudakin et al.,
1995; Hershko and Ciechanover, 1998).
Our current understanding of the mechanism by which
the APC/C is inhibited by unaligned chromosomes has come
primarily from studies of the MAD2 checkpoint protein.
Consistent with the behavior of MAD2 mutants in yeast
(Hoyt et al., 1991; Li and Murray, 1991; He et al., 1997),
disruption of MAD2 function in mammalian cells and 
 
Xe-
nopus
 
 extracts prevented the establishment of a checkpoint
arrest in response to spindle damage (Chen et al., 1998;
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Gorbsky et al., 1998). The ability of MAD2 to selectively
bind unattached kinetochores suggests that one of its func-
tions is to monitor kinetochore–microtubule interactions. In
mammalian cells, the evidence suggests that MAD2 may di-
rectly monitor the microtubule occupancy at kinetochores
such that kinetochores fully saturated with microtubules ex-
hibit no detectable MAD2, whereas MAD2 is prominently
localized to unattached kinetochores (Waters et al., 1998).
How this occurs remains unknown, but MAD2 is sensitive
to microtubule interactions mediated by the kinetochore
motor CENP-E. Depletion of CENP-E from kinetochores
in mammalian cells disrupts chromosome alignment, and
cells become arrested in mitosis with high levels of MAD2 at
unattached kinetochores (Yao et al., 2000). In 
 
Xenopus
 
 ex-
tracts, depletion of CENP-E prevents MAD2 localization to
kinetochores, and thus the extracts fail to arrest in mitosis
when spindle assembly is inhibited (Abrieu et al., 2000). De-
spite the differences between how the checkpoint in these
two experimental systems responds to loss of CENP-E func-
tion, it is clear that CENP-E activity at kinetochores is
linked to MAD2 binding to kinetochores.
In addition to its role at kinetochores, MAD2 is thought
to have a downstream role in directly blocking APC/C activ-
ity. MAD2 was found to bind to the APC/C in cytosol that
was obtained from mitotically arrested HeLa cells (Li et al.,
1997). Addition of excess MAD2 to mitotic egg extracts
blocked exit from mitosis even in the absence of kinetochores
(Chen et al., 1998). Furthermore, MAD2 was found to di-
rectly inhibit the ubiquitin ligase activity of purified APC/C
in vitro (Li et al., 1997; Fang et al., 1998). Interestingly, bac-
terially expressed MAD2 was found to exist as either mono-
mers or tetramers but only the tetrameric form was found to
inhibit the APC/C (Fang et al., 1998). The possibility that
there are inactive and active states of MAD2 provided a
mechanistic explanation for an existing model in which un-
attached kinetochores are envisioned to convert MAD2 into
a form that can inhibit APC/C activity (Gorbsky et al., 1998;
Howell et al., 2000; Shah and Cleveland, 2000). One part of
this model, whereby MAD2 is postulated to cycle on and off
kinetochores, has been confirmed by FRAP experiments that
measured the half-life of kinetochore-bound MAD2 (Howell
et al., 2000). These studies estimated that the half-life of
MAD2 at unattached kinetochores is 
 
 
 
25 s. This rapid
turnover rate was predicted to generate sufficient amounts of
MAD2 to sustain a prolonged inhibition of the APC/C.
Although the collective studies have shed considerable
light on MAD2, whether inhibition of APC/C is specified
solely by MAD2 in vivo is unknown. In yeast and mamma-
lian cells, MAD2 has been shown to interact with the APC/
C through CDC20, a protein that specifies substrate selec-
tivity by the APC/C (Dawson et al., 1995; Visintin et al.,
1997; Fang et al., 1998; Hwang et al., 1998; Kallio et al.,
Figure 1.  Identification of an APC/C inhibitor that copurifies with hBUBR1 kinase. (A) Identification of APC/C inhibitory activity in mitotic 
lysates. Mitotic lysate (S100) was fractionated through a Superose 6 gel filtration column by FPLC and proteins eluting at approximately the 300–
400-kD range were found to inhibit APC/C activity. To maintain some physiological relevance to the APC/C inhibition assays, equal cell 
equivalents of APC/C and the various column fractions were used. Purified mitotic APC/C was incubated for 30 min with either buffer B alone 
(lane 2) or fractions from the 300–400-kD range of the Superose 6 column (lane 4) and then assayed for ubiquitin ligase activity. The same 
column fractions were assayed without addition of APC/C to monitor contaminating APC/C activity (lane 3). A reaction containing only substrate 
served as a negative control (lane 1). Asterisk denotes an iodinated contaminant bacterial protein that is not a substrate for APC/C and was 
excluded from the quantitation. (B) Flow chart of the purification of the APC/C inhibitory complex from HeLa cells. (C) Inhibitor of APC/C 
cofractionates with the hBUBR1 kinase complex. The elution profiles of hBUBR1 (inset) and APC/C inhibitory activity from the final Superose 6 
column is shown. Arrows point to thyroglobulin (670 kD),  -globulin (158 kD), and ovalbumin (44 kD), which served as migration standards. 
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1998; Kim et al., 1998). Furthermore, complexes consisting
of MAD3, BUB3, CDC20, and MAD2 were identified in
budding (Hardwick et al., 2000) and fission yeasts (Hard-
wick, K.G., personal communications). In mitotic HeLa
cells, APC/C is associated with the hBUBR1 checkpoint ki-
nase (Chan et al., 1999). This observation suggests that inhi-
bition of APC/C in vivo might be achieved through more
complex schemes. To obtain some insights into how APC/C
is inhibited by the checkpoint in vivo, we set out to identify
factors from mitotically arrested HeLa cells that inhibited
APC/C. This search yielded a single stable complex named
the mitotic checkpoint complex (MCC), consisting of the
proteins hBUBR1, hBUB3, CDC20, and MAD2. We re-
port here on the identification and characterization of
MCC, and present evidence that this is a physiologically rel-
evant inhibitor of the APC/C.
 
Results
 
Identification of an APC/C inhibitor that contains 
hBUBR1 kinase
 
We undertook a biochemical approach to identify factors in
mitotically arrested cells that were responsible for inhibiting
the APC/C in vivo. HeLa cells were chosen because they ex-
hibit a robust checkpoint arrest in response to spindle or ki-
netochore defects. Lysates prepared from mitotically blocked
cells were chromatographed through a gel filtration column
and fractions were tested for their ability to inhibit APC/C
in a standard in vitro assay (Sudakin et al., 1995). Our assay
relied on APC/C that was partially purified from mitotic
HeLa cells, and was based on a protocol used to purify the
cyclosome from clam oocytes (Sudakin et al., 1995). Iodi-
nated substrate consisting of protein A fused to the destruc-
tion box of cyclin B1 allowed quantitation of the APC/C ac-
tivity (Glotzer et al., 1991). We found that fractions eluting
from the 400-kD region of the gel filtration column strongly
inhibited APC/C activity (Fig. 1 A, lane 4) whereas no in-
hibitory activity was detectable from other fractions from
the column (unpublished data). The inhibitory factor eluted
at a position that was very close to that described previously
for the mitotic checkpoint kinase hBUBR1 (Chan et al.,
1999). We attempted to separate the inhibitor away from
hBUBR1 by using additional column chromatography (Fig.
1 B). At each of the three successive chromatographic steps,
the peaks of APC/C inhibitory activity and hBUBR1 coin-
cided. The results obtained from the final Superose 6 col-
umn show coelution of the APC/C inhibitor (MCC) and
hBUBR1 (Fig. 1 C).
To test whether hBUBR1 is an essential component of
MCC, fractions containing high levels of MCC activity were
immunodepleted of hBUBR1 and the remaining supernatant
was tested for APC/C inhibitory activity. Incubation of
MCC with nonimmune IgG did not deplete hBUBR1 or re-
duce its inhibitory activity relative to untreated MCC (Fig. 2
A, compare lanes 2 and 3). In contrast, MCC fractions that
were immunodepleted of hBUBR1 did not block APC/C ac-
tivity to the same extent as mock-depleted or untreated MCC
(Fig. 2 A, compare lane 4 with lanes 2 and 3). Because
hBUBR1 was not completely depleted from this MCC frac-
tion (
 
 
 
25% of the input hBUBR1 was still detected by
Western analysis, Fig. 2 A, upper panel), some residual APC/C
inhibitory activity was detected when compared with APC/C
that was incubated with buffer alone (Fig. 2 A, compare lanes
1 and 4, Fig. 2 B). These results show that hBUBR1 or an as-
sociated factor is essential for MCC activity.
 
MCC consists of multiple checkpoint proteins
 
To further characterize the composition of MCC, we
probed the complex for MAD2. Fractionation of crude mi-
totic lysates through a Superose 6 column showed that the
vast majority of MAD2 was found as monomers. However,
some MAD2 (
 
 
 
5% of total) comigrated with the MCC and
the APC/C (Fig. 3 A). MAD2 was determined to be part of
MCC, as it was detected in hBUBR1 immunoprecipitates
obtained from fractions containing MCC (Fig. 3 B). Fur-
thermore, MCC was found to contain CDC20, an activator
of the APC/C that has been shown to target MAD2 to the
APC/C (Fang et al., 1998; Wassmann and Benezra, 1998).
Consistent with the previous data that showed that hBUB3
was associated with hBUBR1 (Chan et al., 1999, Taylor et
al., 1998), hBUB3 was also present in the MCC (Fig. 3 B).
The presence of MAD2 in MCC was verified in immuno-
precipitation experiments using anti-MAD2 antibodies. The
Figure 2.  MCC inhibition of the APC/C requires hBUBR1. Purified 
mitotic APC/C was incubated in the presence of buffer (lane 1), MCC 
(lane 2), MCC that was mock depleted with nonimmune IgG (lane 3) or 
immunodepleted with hBUBR1 antibodies (lane 4), and then 
assayed for ubiquitin ligase activity. (A) Ubiquitination assay. Mock- 
and hBUBR1-immunodepleted supernatants were probed for hBUBR1 
(top panel). Asterisk denotes the contaminant iodinated protein. (B) 
Quantification of the ubiquitination assay on phosphorimager. 
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MAD2 immunoprecipitates contained all four MCC sub-
units (Fig. 3 B). Importantly, we did not detect hBUB1 or
MAD1 in the MCC (unpublished data) despite the fact that
they have been shown to interact with some of the MCC
subunits (hBUB1 with hBUB3, and MAD1with MAD2).
Our recently published data indicate that MAD1 binds
MAD2 but not CDC20 (Campbell et al., 2001). This sug-
gests that hBUB1 and MAD1 form complexes distinct from
the MCC.
The MCC and APC/C migrated closely to each other
through the gel filtration column so it was critical to obtain
additional evidence that the interaction between hBUBR1–
hBUB3 and CDC20–MAD2 did not occur through their
mutual association with the APC/C. MCC and APC/C frac-
tions were pooled from the Superose 6 column and rechro-
matographed through a MonoQ column. Western blots of
the eluted fractions showed that the four MCC subunits
could be separated from the APC/C as determined by lack of
CDC27 immunoreactivity and ubiquitin ligase activity (Fig.
3 C, fractions 27 and 28). Only fractions containing the
four MCC subunits exhibited APC inhibitory activity (un-
published data). We found that some of the MCC subunits
did not comigrate with each other, most likely because they
had dissociated. Paradoxically, fractions containing active
APC/C were found to also contain MCC (Fig. 3 C, frac-
tions 40–42). We reasoned that the ability of APC/C to re-
main active in the presence of MCC could be explained by
the existence of both active and inactive populations of
Figure 3. APC/C inhibitor is a complex of mitotic checkpoint proteins. (A) MAD2 comigrates with the hBUBR1 kinase complex. Mitotic 
HeLa extracts were separated through a Superose 6 column and the column fractions were probed for MAD2, hBUBR1, and the APC7. 
Fractions exhibiting APC/C inhibitory activity are denoted as MCC. (B) MCC consists of hBUBR1, hBUB3, MAD2, and CDC20. Fractions 
eluting from the 300–400-kD region of the Superose 6 column in A that exhibited APC/C inhibitory activity were pooled and immunoprecipitated 
with nonimmune IgG, anti-hBUBR1, and anti-MAD2 antibodies, washed, and probed with for hBUBR1, hBUB3, MAD2, and CDC20. (C) 
MCC can exist independently of APC/C. Fractions 19–28 from the Superose 6 column shown in A were combined and rechromatographed 
through a MonoQ anion exchange column by FPLC. Fractions were assayed for APC/C activity (solid line) and probed for hBUBR1, hBUB3, 
CDC20, MAD2, and CDC27 by Western blots. (D) Separation of active and inactive APC/C. Fractions 40–42 from the MonoQ column shown 
in C that exhibited APC/C activity and MCC were immunodepleted successively with anti-hBUBR1 and anti-CDC20 antibodies. The ubiquitin 
ligase activity was tested in the supernatants and immunoprecipitates. (Lane 1) Input APC/C activity; (lanes 2 and 3, respectively) APC/C 
activity in the supernatants after depletion of hBUBR1 and CDC20; (lanes 4 and 5, respectively) APC/C activity associated with corresponding 
hBUBR1 and CDC20 immunoprecipitates; and (lane 6) immunoprecipitate performed with nonimmune IgG. hBUBR1, CDC20, and nonimmune 
IgG immunoprecipitates were probed for CDC27 to estimate relative amount of APC/C (bottom panel). Asterisk denotes the contaminant 
iodinated protein. 
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APC/C in these fractions. To test this hypothesis, we immu-
noprecipitated the MCC from these fractions with hBUBR1
antibodies, and found that a small fraction of the input
APC/C activity was detected in the hBUBR1 immunopre-
cipitates as nearly all of the input APC/C activity remained
in the supernatant (Fig. 3 D, lanes 2 and 4). The majority of
the APC/C activity in this supernatant was significantly de-
pleted after immunoprecipitation with CDC20 antibodies
(Fig. 3 D, lane 3), as it was mostly recovered in the CDC20
immunoprecipitates (Fig. 3 D, lane 5). When the APC/C
activities associated with the hBUBR1 and CDC20 immu-
noprecipitates were normalized to the amount of CDC27
that coimmunoprecipitated with each antibody, we estimate
that the APC/C activity that was associated with hBUBR1
(MCC) was approximately sixfold weaker than the APC/C
that was not associated with hBUBR1. This is likely an un-
derestimate, as the APC/C activity detected in the hBUBR1
beads may have been due to dissociation of the MCC. Re-
gardless, these data provide further evidence that MCC is
likely a potent inhibitor of the APC/C in vivo.
Next, we sought evidence to directly support our finding
that hBUBR1 is part of the inhibitory complex that blocks
APC/C activity. Initial attempts to purify MCC with the
hBUBR1 antibodies were unsuccessful because the harsh
conditions required to elute hBUBR1 from the antibody-
linked beads destroyed the complex. An alternative approach
was to express a glutathione 
 
S
 
-transferase (GST)-tagged
hBUBR1 in human embryonic kidney cell line HEK293T
and then use glutathione beads to affinity purify it along
with the appropriate subunits from extracts of transfected
cells (Fig. 4, A and B). Western blot analysis confirmed that
the affinity-purified GST–hBUBR1 formed the MCC, as it
contained endogenous hBUBR1, hBUB3, CDC20, and
MAD2. As shown previously, only a small fraction of the to-
tal pool of MAD2 was associated with GST–hBUBR1:
MCC (Fig. 4 A, lane 3). All of these associations are specific
to hBUBR1, as these proteins did not associate with GST
alone (Fig. 4 A, lane 1). Purified GST–hBUBR1:MCC was
found to inhibit ubiquitin ligase activity of the APC/C (Fig.
4 B, lane 5) as was seen with conventionally purified MCC
(Fig. 4 B, lane 4). GST purified from transfected cells did
not exhibit significant inhibitory activity (Fig. 4 B, lane 3).
 
MCC is a more potent inhibitor than 
recombinant MAD2
 
Recombinant MAD2 purified from bacteria can exist as
monomers and tetramers, but only tetrameric MAD2 was
found to inhibit APC/C in vitro (Fang et al., 1998). Gel fil-
tration of mitotic HeLa extracts cells showed that 
 
 
 
90% of
MAD2 is not associated with MCC or APC/C (Fig. 3 A)
and these fractions did not inhibit APC/C (unpublished
data). To understand why recombinant MAD2 can inhibit
APC/C whereas MAD2 in HeLa cells cannot, we compared
the inhibitory activities between MCC and recombinant
MAD2. Optimally, this comparison should be made based
on protein concentration. However, we could not estimate
the amount of MCC as our preparations were not purified to
homogeneity. Therefore, we standardized the inhibitory ac-
tivities using MAD2 levels. First, we estimated the amount
of MAD2 that was present in MCC by quantitative immu-
noblots using known amounts of recombinant MAD2 (Fig.
5 A). We then compared the inhibitory activities obtained
with different amounts of MCC or recombinant tetrameric
MAD2 and determined the amount of each inhibitor that
gave comparable activities (Fig. 5 B). Based on this analysis,
we estimated that the inhibitory activity of the MCC is
 
 
 
3,000-fold greater than recombinant MAD2 oligomers.
Next, we estimated the stoichiometry of the MCC sub-
units to see if there was any evidence for the existence of
MAD2 oligomers. MCC was immunoprecipitated from ly-
sates prepared from 
 
35
 
S-Trans–labeled HeLa cells and the
radioactivity in each subunit was counted (Fig. 5 C). When
the counts were normalized to the methionine and cysteine
contents in hBUBR1, hBUB3, CDC20, and MAD2 (40,
Figure 4.  Affinity-purified GST–hBUBR1:MCC inhibits APC/C. 
(A) GST–hBUBR1 is associated with the MCC. A GST–hBUBR1 
construct was transfected into cells and the protein was affinity
purified using glutathione beads. Affinity-purified GST–hBUBR1 
(lane 3) and the remaining supernatant (lane 4) were probed for 
hBUBR1, hBUB3, CDC20, and MAD2. In parallel, a GST construct 
was transfected and the affinity-purified GST (lane 1) and the 
remaining supernatant (lane 2) was probed with the same antibodies 
and a GST antibody to confirm expression of GST in transfected 
cells. The black arrowhead points to endogenous hBUBR1 and the 
open arrowheads point to GST–hBUBR1 and its degradation product 
(as confirmed by GST Western blot, unpublished data). (B) Affinity-
purified GST–hBUBR1:MCC inhibits APC/C. Mitotic APC/C (lane 2) 
was incubated with GST (lane 3), conventionally purified MCC 
(lane 4), and GST-MCC (lane 5) and assayed for ubiquitin ligase 
activity. A control reaction lacking APC/C (lane 1) provided the 
level of input substrate that was used for calculating APC/C activity 
in the various reactions. 
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13, 14, and 4, respectively, without initiating Met), we ob-
tained a ratio of 1.4
 
  
 
 0.3:1 
 
  
 
0.3:1 
 
  
 
0.2:1.2 
 
 
 
 0.2. A
complex with such a ratio would have a molecular mass of
 
 
 
300 kD. Therefore, it is unlikely that MAD2 oligomers
exist in the MCC.
It is noteworthy that our radiolabeled immunoprecipi-
tate contained additional prominent bands. As hBUBR1 is
known to form a separate complex with CENP-E (which
elutes in the void of Superose 6 columns), these complexes
were likely to be present in the immunoprecipitates. These
additional hBUBR1 complexes explain the higher stoichi-
ometry of hBUBR1 in our calculations. If this is taken into
account, we estimate that the MCC subunits exist in near
equal stoichiometry. Regardless, the results obtained from
the radiolabeling experiment do not support the presence of
oligomeric forms of MAD2 in the MCC. Our data show
that hBUBR1 forms additional uncharacterized complexes
in HeLa cells (Fig. 3 C, fractions 32–35); the complexes
possessed no inhibitory activity (unpublished data). The
identity and functions of these complexes remain to be elu-
cidated. We suggest that the existence of the additional com-
plexes contributed to an increased amount of hBUBR1 in
the calculated MCC ratio presented above. Another possibil-
ity is that the MCC contains yet unidentified subunits. The
complex migrates at 400 kD, whereas its molecular mass es-
timated by our radiolabeling analysis gives a molecular mass
of 
 
 
 
300 kD.
 
MCC is expressed throughout the cell cycle but only 
targets mitotic APC/C
 
We showed previously that the 400-kD hBUBR1 complex
was present in both interphase and mitotic cells (Chan et al.,
1999). Given that hBUBR1 was found to associate with the
APC/C only in mitosis (Chan et al., 1999), we expected that
only the mitotic form of the MCC would inhibit the APC/C.
Surprisingly, hBUBR1 complex isolated from interphase
HeLa cells (synchronized in the G1/S boundary) inhibited
APC/C activity and contained the same subunits found in
mitotic MCC (unpublished data). Furthermore, both inter-
phase and mitotic forms of MCC exhibited similar activities
when equivalent amounts of hBUBR1 were tested (Fig. 6
A). Although this MCC preparation was obtained from cells
arrested at the G1/S boundary, analysis of synchronized cells
obtained by centrifugal elutriation showed that MCC is
present in all stages of the cell cycle (unpublished data).
We reasoned that if MCC activity is not subject to cell cy-
cle regulation, perhaps the sensitivity of the APC/C to MCC
inhibition differed between interphase and mitosis. This
possibility was confirmed as only APC/C that was obtained
from mitotic cells was efficiently inhibited by MCC,
whereas APC/C that was purified from interphase cells was
only modestly inhibited by MCC (Fig. 6 B). This modest
level of inhibition is likely contributed by the APC/C
present in the small fraction of mitotic cells in the asynchro-
nous cell population. As several subunits of the APC/C are
Figure 5.  Characterization of the MCC. (A) Estimation of MAD2 content in MCC. Quantitative immunoblot of purified MCC with known 
amounts of recombinant MAD2. Recombinant (His) 6-tagged MAD2 migrated slower than native MAD2. (B) Comparison of APC/C inhibitory 
activity between the recombinant oligomeric MAD2 and purified MCC. Increasing amounts of oligomeric MAD2 and purified MCC were 
added to the APC/C assay to compare inhibitory activities. Phosphorimage of the APC/C reactions (upper panel) was quantified to determine 
the amount of recombinant MAD2 and MCC required to achieve equivalent levels of inhibition (lower panel). (C) MCC subunits exist in near 
equal stoichiometry. HeLa cells were labeled in 
35S-Trans label for 6 h and mitotic and interphase cells were separated and then incubated 
with nonimmune IgG or hBUBR1 antibodies. Phosphorimage of the immunoprecipitate obtained from mitotic cells shows the radiolabeled 
hBUBR1, hBUB3, MAD2, and CDC20. The counts from each subunit were normalized to their cysteine and methionine contents (without 
initiating Met) to estimate their stoichiometry. 
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hyperphosphorylated during mitosis (King et al., 1995; La-
hav-Baratz et al., 1995; Descombes and Nigg, 1998; Kotani
et al., 1999), we examined whether these modifications
might specify interactions between MCC and the mitotic
APC/C. Mitotic lysates were fractionated through a Super-
ose 6 column and the portion containing intact APC was
immunoprecipitated with hBUBR1 antibodies. As shown
previously, hBUBR1 was associated with the APC/C as de-
termined by the presence of the APC subunits CDC27,
CDC16, and APC7 (Fig. 6 C). However, hBUBR1 was
found to associate preferentially with APC that contained
hyperphosphorylated CDC27 despite the presence of APC
that contained unphosphorylated CDC27 (Fig. 6 C). Thus,
mitotic phosphorylation of APC/C might specify its inhibi-
tion by the MCC.
 
Sorting out the interactions between chromosomes, 
APC/C, and MCC
 
The ability of MCC from interphase cells to block APC/C
shows that its activity does not require the presence of unat-
tached kinetochores, as mature kinetochores are not found
until mitosis. To clarify the interactions between MCC,
APC/C, and kinetochores, we set out to reconstitute the
checkpoint inhibition of the APC/C in lysates prepared
from HeLa cells. Kinetic studies showed that the APC/C ac-
 
tivity in crude mitotic lysates exhibited a reproducible lag of
 
 
 
15 min, compared with the APC/C activity in lysates pre-
pared from asynchronous cells that were 
 
 
 
90% interphase
(Fig. 7 A, compare 
 
  
 
and 
 
 
 
). The initial lag seen in the mi-
totic lysates may have been due to checkpoint inhibition, as
lysates were prepared from mitotically arrested cells whose
APC/C is associated with MCC. In the absence of chromo-
somes, the checkpoint inhibition cannot be sustained and
the APC/C eventually recovers its activity. This was con-
firmed when addition of purified chromosomes to the mi-
totic lysate suppressed the reactivation of ACP/C (Fig. 7 A,
 
 
 
). Chromosomes do not permanently inactivate the APC/C,
as APC/C was reactivated when chromosomes were removed
from during the incubation (unpublished data). Chromo-
somes were only effective in mitotic lysates as they modestly
reduced APC/C activity in asynchronous lysates (Fig. 7 A,
 
 
 
). This modest reduction can be attributed to the small
fraction of mitotic cells that were present in the asynchro-
nous population.
The ability of APC/C to recover its activity in the absence
of chromosomes suggested that MCC interactions with
APC/C are likely labile, as might be expected for a compo-
nent of the checkpoint. To learn more about the role of
chromosomes in suppressing the reactivation of APC/C, we
tested whether chromosomes enhanced the inhibitory activ-
Figure 6.  Regulation of the MCC. (A) MCC is present and active in interphase HeLa cells. hBUBR1 complex was purified from HeLa cells 
that were arrested at the G1/S boundary by a double thymidine block. The hBUBR1 and APC/C inhibitor profiles (tested by APC/C partially 
purified on gel filtration column) from the final Superose 6 column are shown. (B) Only APC/C from mitotic cells is sensitive to inhibition by 
MCC. APC/C purified from mitotic (M) and interphase (I) cells were incubated in the absence and presence of the MCC that was purified from 
interphase HeLa cells. Relative APC/C activity denotes the ratio of the ubiquitin ligase activity in reactions performed in the presence and 
absence of MCC. (C) hBUBR1 binds preferentially APC/C that contains hyperphosphorylated CDC27. Mitotic HeLa lysates were fractionated 
through a Superose 6 column as described and the portion containing intact APC was immunoprecipitated with hBUBR1 antibodies. The 
immunoprecipitate (IP) and remaining supernatant (Sup) were separated on SDS-PAGE and probed with hBUBR1, CDC27, CDC16, and 
APC7 antibodies. 
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ity of MCC or inhibited the stimulatory activity of CDC20.
APC/C that is purified from cells is depleted of its activator
CDC20, as addition of recombinant CDC20 significantly
stimulates APC/C activity (Fang et al., 1998). Preincubation
of the APC/C with chromosomes led to significant inhibi-
tion of the ubiquitination activity (Fig. 7 B, compare lanes 1
and 2). To test whether chromosomes blocked APC/C
through CDC20, in vitro–translated CDC20 was preincu-
bated with chromosomes and then assayed for its ability to
stimulate APC/C that was partially purified from mitotic
cells. No difference in stimulatory effect was observed be-
tween untreated and treated CDC20 (Fig. 7 B, compare
lanes 1 and 4). We next preincubated chromosomes with
purified MCC to test whether its inhibitory activity might
be enhanced. No enhancement of MCC inhibitory activity
was observed compared with untreated MCC (for this assay,
we predetermined the amount of MCC that produced a 50–
60% inhibition of APC/C activity) (Fig. 7 B, compare lanes
5 and 6). To address the question of whether a soluble factor
emitting from chromosomes is responsible for the inhibition
of the APC/C, the chromosome sample was preincubated
for 30 min at 30
 
 
 
C. The chromosomes were removed by
centrifugation and we found no significant inhibitory activ-
ity in the remaining supernatant (Fig. 7 B, compare 1 and
3). All reactions were supplemented with CDC20 to main-
tain consistency with the samples where preincubation of
CDC20 with chromosomes has been tested.
We next attempted to reconstitute the suppression of
APC/C activity observed in crude lysates by using purified
components. It was important to verify that the chromo-
some-induced inhibition of the APC/C activity was not
caused by unidentified factors in the crude preparation. As in
crude mitotic lysates, we found that chromosomes are able to
effectively sustain the APC/C inhibition in a highly purified
sample (Fig. 7 C). Given that chromosomes did not exert an
effect on MCC or CDC20, its ability to suppress the activa-
tion of APC/C maybe mediated through the APC/C.
 
Discussion
 
MCC is likely the APC/C inhibitor in vivo
 
We have isolated from HeLa cells a complex consisting of
hBUBR1, hBUB3, MAD2, and CDC20 that is responsible
for inhibiting the APC/C in mitotically arrested cells. MCC
obtained by conventional biochemical purification or by af-
finity purification blocked APC/C in an in vitro assay. In
addition, we found that the majority of the APC/C in a mi-
totic cell is bound to MCC. However, this complex exhib-
ited very little activity (
 
 
 
5% of the total) when compared
with APC/C that lacked MCC. Although many reports
show that recombinant MAD2 can directly inhibit APC/C,
we determined that the inhibitory activity was over three or-
ders of magnitude (
 
 
 
3,000-fold) weaker than the MCC.
This difference in activity accounts for why the population
of free MAD2 in cells, which is present at an 
 
 
 
20–50-fold
 
determine the APC/C activity. In all experiments presented in the 
figure the Ub–substrate conjugates were visualized and quantified as 
described above.
 
Figure 7. 
 
Chromosomes inhibit APC/C. 
 
(A) Chromosomes prolong 
the inhibition of the APC/C activity in mitotic lysates. APC/C activity 
in lysates prepared from interphase (
 
 
 
) and mitotic (
 
 
 
) cells were 
monitored for up to 60 min. The same lysates were assayed for ACP/C 
activity in the presence of chromosomes (
 
 
 
 and 
 
 
 
). (B) Chromo-
somes inhibit APC/C fraction directly. Partially purified mitotic APC/C 
(gel filtration form of the APC/C was prepared as described above), 
MCC and in vitro–translated CDC20 were preincubated, respectively, 
in the presence or absence of chromosomes at 300
 
 
 
C. Upon 
completion of the preincubation, the APC/C inhibitory assays were 
assembled as described below. After 30 min, E1, E2-C, and radio-
labeled substrate were added to initiate the ubiquitin ligase reaction 
and APC/C activity was determined over the course of 30 min. (1) 
APC. APC/C was preincubated alone; (2) APC
 
 
 
CR. APC/C was 
preincubated with chromosomes; (3) APC
 
 
 
CR SUP. Chromosomes 
were preincubated, the mix was centrifuged for 10 min at 14,000 
rpm to remove chromosomes, and the supernatant was tested for the 
APC/C inhibitory activity; (4) APC
 
 
 
CDC20/CR. In vitro–translated 
CDC20 was preincubated with chromosomes, the mix was centrifuged 
for 10 min at 14.000 rpm to remove chromosomes, and the 
supernatant was tested for the APC/C inhibitory activity; (5) 
APC
 
 
 
MCC. MCC was preincubated alone; (6) APC
 
 
 
MCC/CR. 
MCC was preincubated with chromosomes, the mix was centrifuged 
for 10 min at 14,000 rpm to remove chromosomes, and the 
supernatant was tested for the APC/C inhibitory activity. All reactions 
were supplemented with CDC20 to maintain the same concentration 
with the samples where preincubation of CDC20 with chromosomes 
has been tested. (C) Chromosomes inhibit highly purified APC/C. Gel 
filtration fraction of the APC/C was further purified on MonoQ anion 
exchange FPLC column as described above. The APC/C was pre-
incubated with or without chromosomes and the ubiquitination 
reaction was initiated upon addition of all necessary ingredients as 
described above. 0, 5, 10, and 30 min time points were taken to  
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higher level than the amount of MAD2 in MCC, cannot
block APC/C in vivo. We have determined that the concen-
tration of MAD2 in mitotic lysates prepared from HeLa
cells is 
 
 
 
400 nM
 
 
 
(unpublished data), but this is about five-
fold lower than the concentration of recombinant MAD2
that is required to inhibit APC/C in vitro. Thus, HeLa cells
simply do not express MAD2 at the levels that are required
to inhibit APC/C in vitro.
Although oligomerization of recombinant MAD2 was
found to enhance its ability to inhibit APC/C activity (Fang
et al., 1998), it cannot account for the inhibitory activity of
the MCC. Based on the near equal stoichiometry of the
MCC subunits, it is unlikely that MAD2 oligomers are
present in the MCC despite its ability to oligomerize in bac-
teria (Fang et al., 1998). It is unclear whether the inhibitory
activity of MAD2 is enhanced through its association with
the other MCC subunits, or whether the other subunits of
MCC also directly block APC/C activity. Taken together,
our data strongly suggest that MCC is the physiologically
relevant inhibitor of the APC/C in HeLa cells. Interestingly,
a similar complex consisting of MAD3, CDC20, and MAD2
has been identified in yeast but its role in regulating APC/C
has not been elucidated (Hardwick et al., 2000). It appears
that the MCC may be conserved throughout evolution.
It is noteworthy that we did not detect MAD1 in MCC
(unpublished data) even though MAD1 and MAD2 form a
complex in vivo (Chen et al., 1998, 1999;
 
 
 
Jin et al., 1998;
Campbell et al., 2001). Studies in 
 
Xenopus
 
 extracts suggest
that MAD1 specifies kinetochore binding by MAD2 but
that is not directly involved in inhibiting the APC/C (Chen
et al., 1998). We have also not detected the presence of
checkpoint proteins such as hBUB1, hZW10, or hROD in
the MCC. Therefore, these components are likely to provide
functions that are distinct from the MCC.
We believe that MCC inhibits APC/C by directly binding
to it rather than via catalytic inactivation. This conclusion is
based on the finding that the intracellular concentration of
hBUBR1 and APC/C are roughly the same (
 
 
 
52 and 65
nM for hBUBR1 and CDC27 in crude lysate, respectively;
ratio 1:1 in anti-hBUBR1 immunoprecipitates from whole
mitotic lysate; unpublished data). Our unpublished data in-
dicate that there is 
 
 
 
400 nM of MAD2 in mitotic HeLa ly-
sates. The gel filtration profiles show that only 5–10% of the
total MAD2 is a part of high molecular mass complexes and
comigrates with APC/C and MCC (Fig. 3 A). Given the
hBUBR1 and CDC27 concentrations we have a roughly
equal ratio between hBUBR1, CDC27, and “active” MAD2
in our extracts (
 
 
 
52, 65, and 20–40 nM, respectively). This
ratio of hBUBR1 to active MAD2 is similar to our estimate
using radiolabeled proteins.
Examination of the MCC and APC/C profiles in a MonoQ
column showed that MCC was associated with 
 
 
 
75% of
the APC/C (Fig. 3 D). However, the remaining 25% of the
APC/C most likely lost its association with its MCC, as we
found MCC in fractions that did not contain any APC/C
(Fig. 3 C). We had relied previously on immunoprecipitation
to estimate that 
 
 
 
25% of the APC/C was bound to hBUBR1
(Chan et al., 1999). This is likely to be an underestimate, as
we now know that the conditions used to wash the immuno-
precipitate dissociated much of the APC/C from hBUBR1.
The identification of the molecular interactions among the
various subunits within APC/C and MCC will be crucial for
understanding the mechanism of inhibition.
 
Roles of MCC and kinetochores in inhibition of APC/C
 
The finding that MCC is present during interphase and can
inhibit the APC/C was unexpected because kinetochores
(which are not present during interphase) are thought to gen-
erate the inhibitor of the APC/C. However, we found that
only APC/C from mitotic cells was sensitive to MCC inhibi-
tion. These findings have changed our view of the checkpoint
pathway in two important ways (Fig. 8). First, our data sug-
gest that the formation and activity of the APC/C inhibitor
can be uncoupled from kinetochores. This may be an impor-
tant feature considering that APC/C is known to be activated
at the onset of mitosis. The existence of a preformed pool of
inhibitor would rapidly block precocious ubiquitination activ-
ity by the APC/C at the onset of mitosis. It is noteworthy that
only the mitotically modified form of the APC/C can be in-
hibited (Fig. 6, B and C; Fig. 7 A), which can explain why the
preformed pool of MCC doesn’t inhibit APC before mitosis.
By necessity, the inhibition must be reversible so that APC/C
can be activated once cells are ready to exit mitosis. We believe
that in vivo, the interaction between APC/C and MCC is
quite labile in the absence of unattached kinetochores. This
would explain why APC/C that is purified from mitotic cells
exhibits a lag before it becomes reactivated.
We also propose that the role of unattached kinetochores
is to sustain the inhibition of APC/C by MCC. We found
Figure 8.  Model for MCC function and regulation. MCC is 
present throughout the cell cycle but is incapable of inhibiting 
APC/C until it has undergone mitotic modifications. APC/C is 
normally rapidly activated in mitosis by phosphorylations and 
association with CDC20. These modifications may also be recog-
nized by the MCC so that APC/C is prevented from ubiquitinating 
target proteins until all chromosomes are aligned. We speculate that 
the interaction between MCC and APC/C is not stable so APC/C is not 
permanently inhibited. In the presence of unattached kinetochores 
( ), signals initiated at kinetochores modify the APC/C or APC-bound 
MCC to enhance their interactions and thus prolong its inhibition. 
The signal from the kinetochore can either be MAD2 as proposed or 
a kinase cascade that is initiated at the kinetochore by hBUBR1, 
hBUB1, or other kinases. After chromosomes align, the signal from 
kinetochores decays along with the modifications. The MCC then 
dissociates and APC/C becomes active to drive cells out of mitosis. 
We believe that MCC may not inhibit APC/C during interphase 
because it either lacks the appropriate phosphorylations or the APC/C 
is bound to a different substrate specificity factor, CDH1. 
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that APC/C activity in mitotic lysates and purified mitotic
APC/C was suppressed upon addition of chromosomes. We
propose that the “wait anaphase” signal that is produced by
unattached kinetochores enhances or prolongs the inhibition
of the APC/C mediated by the MCC. Given that APC/C
copurifies with MCC (Fig. 3, C and D), we cannot as yet
clearly distinguish whether the target is the MCC or the
APC/C. We examined the effect of chromosomes on puri-
fied MCC and CDC20 to address this issue and found that
neither MCC inhibitory activity nor CDC20 stimulatory
activity was affected by chromosomes. This leaves open the
possibility that chromosomes target subunits of the APC/C
to sensitize it to prolonged inhibition by MCC.
 
The role of the kinetochore in generating wait 
anaphase signal
 
The biochemical nature of the wait anaphase signal that is
generated at kinetochores remains to be elucidated but it is
likely to involve many of the checkpoint proteins that reside
there. FRAP analysis of MAD2 showed that its half-life at
kinetochores is 
 
 
 
25 s, and that 
 
 
 
1,300 molecules are
present on kinetochores at any given time (Howell et al.,
2000). The rapid turnover rate supports a model whereby
unattached kinetochores catalytically convert MAD2 into a
form that inhibits the APC/C upon its release from kineto-
chores (Chen et al., 1998; Gorbsky et al., 1998; Howell et
al., 2000). Our data cannot eliminate this possibility despite
the fact that kinetochores are not required for MCC forma-
tion or activity. In light of our findings, we propose that
MAD2 that is derived from kinetochores may enhance the
sensitivity of the APC/C to the inhibitory action of MCC.
As the fate of MAD2 after it has dissociated from kineto-
chores is not known, other possibilities remain open. An
alternative view is that the APC/C inhibition is mediated
by checkpoint kinases such as BUBR1 and BUB1 that re-
side at kinetochores. In this scenario, MAD2 could regu-
late these kinetochore-associated kinases such that its pres-
ence at unattached kinetochores is required to maintain a
threshold level of kinase activity. It is noteworthy that
hBUBR1 that is associated with kinetochores becomes
quantitatively hyperphosphorylated within 15 min after
disruption of microtubule attachments (Chan et al., 1999).
This may contribute to MAD2 binding, as in vitro studies
show that MAD2 will only bind to kinetochores that are
phosphorylated (Waters et al., 1998). We speculate that
hyperphosphorylation of hBUBR1 stimulates its kinase ac-
tivity that is required for generating the wait anaphase sig-
nal. In vivo, efficient phosphorylation of APC/C by ki-
netochores may be achieved through a kinase cascade. Our
attempt at reconstituting the checkpoint inhibition of
APC/C by adding just chromosomes probably does not re-
flect the in vivo situation. In our experiments, we believe
that chromosomes are directly modifying the APC/C while
in vivo, an occurrence probably accomplished by a signal-
ing cascade amplifying the signal that originates from a sin-
gle unattached kinetochore. Whatever the nature of the
modification that is introduced to the APC/C by kineto-
chores, it must be labile in order to relieve MCC inhibitory
activity upon chromosome alignment.
 
MCC interactions with APC/C
 
Regardless of whether kinetochores modify APC/C to pro-
longed inhibition by the MCC, our data show that APC/C
must undergo mitotic modifications in order for it to be recog-
nized by the MCC. This is supported by the observation that
interphase APC/C was insensitive to inhibition by MCC. The
insensitivity cannot be due simply to the lack of modifications
introduced by kinetochores, as APC/C activity in interphase
lysates was unaffected in the presence of chromosomes. We
believe that the mitotic modifications that target the MCC to
APC/C include phosphorylations of specific APC/C subunits
(King et al., 1995; Lahav-Baratz et al
 
., 
 
1995; Charles et al
 
.,
 
1998;
 
 
 
Descombes
 
 
 
and Nigg
 
, 
 
1998; Kotani
 
 
 
et al
 
., 
 
1999; Shi-
rayama et al., 1998) and its association with CDC20 (Fang et
al., 1998; Shirayama et al., 1998; Chan et al., 1999; Shtein-
berg et al., 1999). The importance of CDC20 in checkpoint
control is highlighted by the finding that certain CDC20 mu-
tants in fission (Kim et al., 1998) and budding yeast (Hwang
et al., 1998; Schott and Hoyt, 1998) exhibit checkpoint de-
fects. Whether this mutation affects formation of an MCC-
like complex (Hardwick et al., 2000; Millband, D., and K.G.
Hardwick, personal communications) or alters the sensitivity
of the APC/C to inhibition by the checkpoint remains to be
clarified. How modifications to the APC/C contribute to rec-
ognition by MCC remains to be determined, but it has been
reported that MAD2, CDC20, and hBUBR1 bind preferen-
tially to mitotically phosphorylated APC/C (Fang et al., 1998;
Kallio et al., 1998; Kotani et al., 1999; Wu et al., 2000). We
suggest that these previously reported findings reflect the
MCC–APC/C association during mitosis. It remains to be
seen whether the modifications that are required for APC/C
activity are also used by the MCC to inhibit the APC/C.
 
Materials and methods
 
Preparation of HeLa extracts
 
Frozen HeLa cell pellets were obtained from the National Cell Culture
Center (Cellex Biosciences). Mitotic extracts were prepared from HeLa
cells exposed to 60 ng/ml nocodazole for 18 h. Interphase extracts were
prepared from cells arrested at the G1/S boundary after double thymidine
block. Cells were washed twice in ice cold PBS, diluted 1:1 with the dis-
ruption buffer (40 mM Hepes, pH 7.4, 10 mM EDTA, 2 mM DTT, and pro-
tease inhibitors), and lysed using a high-pressure nitrogen bomb (Parr In-
struments). 10,000 
 
g
 
 (S10) supernatants were supplemented with glycerol
(10% final concentration) and frozen at 
 
 
 
80
 
 
 
C. To prepare high-speed ex-
tracts, S10 extracts were spun in the ultracentrifuge (Beckman Coulter) at
100,000 
 
g
 
 for 30 min. Final protein concentration of the extracts was 15–
18 mg/ml. All procedures were carried out at 4
 
 
 
C.
 
Purification of mitotic chromosomes
 
Chromosomes were purified from mitotically blocked HeLa cells as de-
scribed (Yen et al., 1991). In brief, HeLa cells were blocked with nocoda-
zole for 18 h, pelleted and hypotonically swollen in RSB (10 mM Tris-HCl,
pH 8.0, 10 mM MgCl
 
2
 
, 10 mM NaCl), and lysed in digitonin containing
buffer A (50 mM Tris-HCl, pH 7.5, 80 mM KCl, 2 mM EGTA, 3 mM sper-
mine, 7.5 mM spermidine, 0.1% digitonin supplemented with 1 
 
 
 
M pep-
statin, 1 
 
 
 
g/ml leupeptin, 1 mM PMSF, 2 
 
 
 
g/ml aprotinin). Cells were lysed
using a dounce (10–12 times using a pestle B) and centrifuged at 500 
 
g
 
 for 5
min to remove nuclei and cell debris. Chromosomes in the supernatant
were pelleted at 1,600 
 
g
 
 for 10 min, washed three times in buffer 3 (50
mM Tris-HCl, pH 7.5, 40 mM KCl, 3 mM spermine, 3.75 mM spermidine
with protease inhibitors), resuspended in buffer 4 (50 mM Tris-HCl, pH
7.5, 20 mM KCl, 3 mM spermine, 3.75 mM spermidine, 15% glycerol with
protease inhibitors), and used immediately or snap frozen. Chromosomes
were examined by DAPI staining and kinetochore integrity was monitored
by staining for CENP-E and various mitotic checkpoint proteins. 
Mitotic checkpoint complex inhibits APC/C |
 
 Sudakin et al. 935
 
Ubiquitination assay and APC/C isolation
 
Crude extracts or purified factors were supplemented with purified E1, E2,
ATP regenerating system, and iodinated protein A–cyclin B substrate
(Glotzer et al., 1991), and the APC/C activity was determined as described
(Sudakin et al., 1995) in final volume of 10 
 
 l. Standard reactions were
performed for 30 min at 30 C but kinetic studies relied on sampling the re-
action at various times. Reaction products were separated by SDS-PAGE
and the dried gel was analyzed with a phosphorimager (Fujix) to quantify
the amount of ubiquitinated substrate. This amount was compared with
the amount of input substrate to obtain the percent of substrate that was
ubiquitinated in each reaction. In all experiments, the percent of substrate
that is conjugated in a positive control reaction that contained APC/C was
set at 1 and served as a reference for the activities obtained in other reac-
tions in the same experiment. Most of the figures show normalized activi-
ties. APC/C was partially purified from HeLa lysates (15 mg total protein)
by fast protein liquid chromatography (FPLC) (Amersham Pharmacia Bio-
tech) using Superose 6 or Superdex 200 gel filtration columns. Gel filtra-
tion columns were eluted with buffer A (50 mM Tris-Cl, pH 7.2, 250 mM
NaCl, 1 mM DTT, 0.2 mg/ml BSA) and fractions exhibiting APC/C activity
were pooled, desalted, and concentrated in buffer B (50 mM Tris-Cl, pH
7.2, 1 mM DTT, 10% glycerol). Further purification of APC/C was
achieved by chromatography through a MonoQ column. Proteins were
eluted with a salt gradient (0.15–0.5 M NaCl) in buffer containing 50 mM
Hepes, pH 7.4, and 1 mM DTT. BSA was added to the fraction collector
tubes (0.2 mg/ml final concentration in collected fractions) and active frac-
tions were washed with buffer B and concentrated. For immunoprecipita-
tion experiments, affinity-purified hBUBR1 or CDC20 antibodies were in-
cubated with APC/C-containing fractions and complexes recovered with
10  l protein A–Sepharose beads. The beads were washed five times in ice
cold PBS containing 0.1% NP-40 and 10% glycerol, and three times in ice
cold buffer containing 50 mM Tris, pH 7.6, 1 mM DTT, 1 mg/ml BSA, and
5% glycerol. After the last wash, the buffer was aspirated completely and
the beads were resuspended in 10  l of the ubiquitination reaction mix as
described above. Samples were incubated at 30 C for 30 min and mixed
gently every 5 min. The reactions were terminated by SDS-PAGE sample
buffer, boiled, and separated by SDS-PAGE. Ub–substrate conjugates were
quantified as described above.
The pET28 plasmid encoding the CDC20 protein was a gift from Dr. M.
Brandeis (Hebrew University, Jerusalem, Israel). The CDC20 protein was
expressed in vitro in a TNT Quick reticulocyte system (Promega).
Purification of the MCC and of recombinant MAD2
APC/C inhibitory activity was recovered in the 20–40% ammonium sulfate
cut of an S100 extract. This was subjected to FPLC separation through Su-
perdex 200 gel filtration, MonoQ anion exchange, and Superose 6 gel fil-
tration columns. Gel filtration columns were eluted with buffer A and frac-
tions were desalted and concentrated in buffer B. MonoQ column was
eluted with shallow salt gradient (0.2–0.5 M NaCl) in buffer B without
glycerol. To show that MCC can exist independently of APC/C, the Super-
ose 6 fractions of MCC and APC/C were pooled and refractionated on
MonoQ anion exchange column by a shallow salt gradient (0.2–0.4 M
NaCl in buffer B). Column fractions were concentrated, desalted into
buffer B, and tested for inhibitory activity in the APC/C assay. During the
initial purification of the inhibitory factor, equal cell equivalents of column
fractions and APC/C were used for the inhibitor assay.
Human MAD2 cDNA was amplified by PCR from HeLa cell cDNA
(CLONTECH Laboratories, Inc.) and cloned into pET28A expression vector
(Novagen). Recombinant protein was expressed in JM109(DE3) and puri-
fied with a nickel–agarose column (QIAGEN). Tetrameric recombinant
hMAD2 was purified by Superdex 75 gel filtration chromatography as de-
scribed (Fang, et al. 1998).
Affinity purification of MCC with GST–hBUBR1
Full-length hBUBR1 cDNA was obtained by digestion of gfp-hBUBR1
(Chan et al., 1998) with BamH1 and KpnI, and transferred to the mamma-
lian GST vector pEBG (gift from N. Grammatikakis, Lankenau Institute for
Medical Research, Wynnewood, PA). Transient transfections were per-
formed by lipofection using Lipofectamine Plus (Life Technologies) as per
manufacturer’s instruction. Transfected HeLa cells were lysed in 50 mM
Tris, pH 7.2, 150 mM NaCl, 1 mM DTT, and protease inhibitors (10  g/ml
AEBSF, 10  g/ml leupeptin, 5  g/ml pepstatin, 5  g/ml chymostatin, 10
 g/ml aprotinin) by repeated freeze and thaw cycles. Lysates were clarified
by spinning at 10,000 g at 4 C. GST–hBUBR1 was affinity purified from
the 10,000 g supernatant by glutathione Sepharose 4B beads (Amersham
Pharmacia Biotech), washed five times with wash buffer (50 mM Tris,
pH7.2, 250 mM NaCl, 1 mM DTT, and protease inhibitors), and eluted
with 10 mM glutathione in lysis buffer. Eluted GST–hBUBR1 was dialyzed
and concentrated using Centricon10 (Millipore) into 50 mM Tris, pH 7.2,
and 1 mM DTT for APC/C assay.
Stoichiometry of MCC
Synchronous populations of HeLa cells released from a G1/S boundary
were labeled in 
35S-Trans label for 6 h. Mitotic and interphase cells were
mechanically separated, lysed in the NP-40 lysis buffer (0.1% NP-40, 10%
glycerol in PBS), and the extracts were then incubated with nonimmune
IgG or hBUBR1 antibodies. Immunoprecipitates were washed five times in
ice cold lysis buffer and separated on SDS-PAGE. Radiolabeled proteins
were visualized and quantified with the phosphorimager (Fujix). Cys  
Met amounts in the MCC proteins (without initiating Met) have been used
to calculate the ratio of the MCC subunits.
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